The table below shows Revolution Medicines, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
-$897.74M
-$557.44M
-$350.57M
-$224.40M
-$147.18M
-$100.06M
Capital expenditure
$15.99M
$10.31M
$7.73M
$10.82M
$6.53M
$2.93M
Investing cash flow
$118.06M
-$554.39M
-$342.60M
-$24.12M
-$142.12M
-$234.23M
Dividends paid
-
-
-
-
RVMD operating cash flow (10-K history)
Revolution Medicines, Inc. reported operating cash flow of -$897.74M for fiscal year 2025. That is down 61.0% from -$557.44M in fiscal 2024. Over the 8 fiscal years shown, operating cash flow declined from $1.21M (FY 2018) to -$897.74M. Figures come from the company's audited annual reports as filed with the SEC.